News >

Devimistat Could Have Practice-Changing Potential in Burkitt Lymphoma

Gina Columbus @ginacolumbusonc
Published: Thursday, Jul 11, 2019

Dr Ariela Noy

Ariela Noy, MD

For patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma who have relapsed on multiagent therapy, devimistat (CPI-613), a novel compound targeting mitochondria has the potential to improve outcomes and increase response rates in an ongoing phase II trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication